PUBLICATIONS

Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma

Mojgan Djavaheri-Mergny, Sylvie Giuriato, Mario P Tschan, Magali Humbert

Cells 2019 Jan 30;8(2):103. doi: 10.3390/cells8020103.

Francesco Maura, Luca Agnelli, Daniel Leongamornlert, Niccolò Bolli, Wing C Chan, Anna Dodero, Cristiana Carniti, Tayla B Heavican, Alessio Pellegrinelli, Giancarlo Pruneri, Adam Butler, Shriram G Bhosle, Annalisa Chiappella, Alice Di Rocco, Pier Luigi Zinzani, Francesco Zaja, Roberto Piva, Giorgio Inghirami, Wenyi Wang, Teresa Palomero, Javeed Iqbal, Antonino Neri, Peter J Campbell, Paolo Corradini

Am J Hematol 2019 Jun;94(6):628-634. doi: 10.1002/ajh.25450. Epub 2019 Mar 19.

Tayla B Heavican, Alyssa Bouska, Jiayu Yu, Waseem Lone, Catalina Amador, Qiang Gong, Weiwei Zhang, Yuping Li, Bhavana J Dave, Maarja-Liisa Nairismägi, Timothy C Greiner, Julie Vose, Dennis D Weisenburger, Cynthia Lachel, Chao Wang, Kai Fu, Jadd M Stevens, Soon Thye Lim, Choon Kiat Ong, Randy D Gascoyne, Edoardo Missiaglia, Francois Lemonnier, Corinne Haioun, Sylvia Hartmann, Martin Bjerregård Pedersen, Maria Antonella Laginestra, Ryan A Wilcox, Bin Tean Teh, Noriaki Yoshida, Koichi Ohshima, Masao Seto, Andreas Rosenwald, German Ott, Elias Campo, Lisa M Rimsza, Elaine S Jaffe, Rita M Braziel, Francesco d’Amore, Giorgio Inghirami, Francesco Bertoni, Laurence de Leval, Philippe Gaulard, Louis M Staudt, Timothy W McKeithan, Stefano Pileri, Wing C Chan, Javeed Iqbal

Blood 2019 Apr 11;133(15):1664-1676. doi: 10.1182/blood-2018-09-872549. Epub 2019 Feb 19.

A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib

Geeta G Sharma, Diego Cortinovis, Francesco Agustoni, Giulia Arosio, Matteo Villa, Nicoletta Cordani, Paolo Bidoli, William H Bisson, Fabio Pagni, Rocco Piazza, Carlo Gambacorti-Passerini, Luca Mologni

J Thorac Oncol 2019 Nov;14(11):e257-e259. doi: 10.1016/j.jtho.2019.06.028.

The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis

Stephen P Ducray, Karthikraj Natarajan, Gavin D Garland, Suzanne D Turner, Gerda Egger

Cancers (Basel) 2019 Jul 30;11(8):1074. doi: 10.3390/cancers11081074.

Commentary on: Deposition of Host Matrix Proteins on Breast Implant Surfaces Facilitates Staphylococcus Epidermidis Biofilm Formation: In Vitro Analysis

Suzanne D Turner

Aesthet Surg J 2020 Feb 17;40(3):296-298. doi: 10.1093/asj/sjz144.

Suzanne Dawn Turner

Aesthet Surg J 2019 Jan 31;39(Suppl_1):S21-S27. doi: 10.1093/asj/sjy229.

Elisabeth S Gruber, Georg Oberhuber, Peter Birner, Michaela Schlederer, Michael Kenn, Wolfgang Schreiner, Gerd Jomrich, Sebastian F Schoppmann, Michael Gnant, William Tse, Lukas Kenner

Cells 2019 Oct 30;8(11):1357. doi: 10.3390/cells8111357.

Petra Aigner, Tatsuaki Mizutani, Jaqueline Horvath, Thomas Eder, Stefan Heber, Karin Lind, Valentin Just, Herwig P Moll, Assa Yeroslaviz, Michael J M Fischer, Lukas Kenner, Balázs Győrffy, Heinz Sill, Florian Grebien, Richard Moriggl, Emilio Casanova, Dagmar Stoiber

Blood Adv 2019 Jul 9;3(13):1989-2002. doi: 10.1182/bloodadvances.2018026385.

Doris Kaltenecker, Madeleine Themanns, Kristina M Mueller, Katrin Spirk, Tobias Suske, Olaf Merkel, Lukas Kenner, Andreia Luís, Andrey Kozlov, Johannes Haybaeck, Mathias Müller, Xiaonan Han, Richard Moriggl

Cytokine 2019 Dec;124:154569. doi: 10.1016/j.cyto.2018.10.010. Epub 2018 Oct 30.

Harald Engelhardt, Dietrich Böse, Mark Petronczki, Dirk Scharn, Gerd Bader, Anke Baum, Andreas Bergner, Eugene Chong, Sandra Döbel, Georg Egger, Christian Engelhardt, Peter Ettmayer, Julian E Fuchs, Thomas Gerstberger, Nina Gonnella, Andreas Grimm, Elisabeth Grondal, Nizar Haddad, Barbara Hopfgartner, Roland Kousek, Mariusz Krawiec, Monika Kriz, Lyne Lamarre, Joyce Leung, Moriz Mayer, Nitinchandra D Patel, Biljana Peric Simov, Jonathan T Reeves, Renate Schnitzer, Andreas Schrenk, Bernadette Sharps, Flavio Solca, Heinz Stadtmüller, Zhulin Tan, Tobias Wunberg, Andreas Zoephel, Darryl B McConnell

J Med Chem 2019 Nov 27;62(22):10272-10293. doi: 10.1021/acs.jmedchem.9b01169. Epub 2019 Nov 13.

DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy

Maria Tsagiopoulou, Nikos Papakonstantinou, Theodoros Moysiadis, Larry Mansouri, Viktor Ljungström, Martí Duran-Ferrer, Andigoni Malousi, Ana C Queirós, Karla Plevova, Sujata Bhoi, Panagoula Kollia, David Oscier, Achilles Anagnostopoulos, Livio Trentin, Matthias Ritgen, Sarka Pospisilova, Niki Stavroyianni, Paolo Ghia, Jose I Martin-Subero, Christiane Pott, Richard Rosenquist, Kostas Stamatopoulos

Clin Epigenetics 2019 Dec 2;11(1):177. doi: 10.1186/s13148-019-0783-1.

Proteomic Phosphosite Analysis Identified Crucial NPM-ALK-Mediated NIPA Serine and Threonine Residues

Anina Gengenbacher, Alina Müller-Rudorf, Teresa Poggio, Linda Gräßel, Veronica I Dumit, Stefanie Kreutmair, Lena J Lippert, Justus Duyster, Anna L Illert

Int J Mol Sci 2019 Aug 20;20(16):4060. doi: 10.3390/ijms20164060.

Chuanjiang Yu, Sivahari P Gorantla, Alina Müller-Rudorf, Tony A Müller, Stefanie Kreutmair, Corinna Albers, Lena Jakob, Lena J Lippert, Zhenyu Yue, Monika Engelhardt, Marie Follo, Robert Zeiser, Tobias B Huber, Justus Duyster, Anna L Illert

Haematologica 2020 May;105(5):1285-1293. doi: 10.3324/haematol.2018.212027. Epub 2019 Aug 8.

Quantification of minimal disseminated disease by quantitative PCR and digital PCR for NPM-ALK as prognostic factor in children with anaplastic large cell lymphoma

Christine Damm-Welk, Nina Kutscher, Martin Zimmermann, Andishe Attarbaschi, Jutta Schieferstein, Fabian Knörr, Ilske Oschlies, Wolfram Klapper, Wilhelm Woessmann

Haematologica 2019 Oct 24;haematol.2019.232314. doi: 10.3324/haematol.2019.232314.

NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia

Alina Rudorf, Tony Andreas Müller, Cathrin Klingeberg, Stefanie Kreutmair, Teresa Poggio, Sivahari Prasad Gorantla, Tamina Rückert, Annette Schmitt-Graeff, Anina Gengenbacher, Peter Paschka, Claudia Baldus, Robert Zeiser, George S Vassiliou, Allan Bradley, Justus Duyster, Anna Lena Illert

Blood 2019 Jul 25;134(4):383-388. doi: 10.1182/blood.2018883140. Epub 2019 Jun 11.

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.

Cervantes-Madrid D, Szydzik J, Lind DE, Borenäs M, Bemark M, Cui J, Palmer RH, Hallberg B.

Sci Rep. 2019 Dec 18;9(1):19353. doi: 10.1038/s41598-019-55060-7.

The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.

Trigg RM, Lee LC, Prokoph N, Jahangiri L, Reynolds CP, Amos Burke GA, Probst NA, Han M, Matthews JD, Kai Lim H, Manners E, Martinez S, Pastor J, Blanco-Aparocio C, Merkel O, de Los Fayos Alonso IG, Kodajova P, Tangermann S, Högler S, Luo J, Kenner L, Turner SD

Nat Commun. 2019 Nov 28;10(1):5428. DOI: 10.1038/s41467-019-13315-x

A compound L1196M/G1202R ALK mutation in an ALK-positive lung cancer patient with acquired resistance to brigatinib also confers primary resistance to lorlatinib.

Geeta G. Sharma, Diego Cortinovis, Francesco Agustoni, Giulia Arosio, Matteo Villa, Nicoletta Cordani, Paolo Bidoli, William H. Bisson, Fabio Pagni, Rocco Piazza, Carlo Gambacorti-Passerini, Luca Mologni.

J Thorac Oncol. 2019 Nov 14. DOI: 10.1016/j.jtho.2019.06.028

NPM-ALK is a key regulator of the oncoprotein FOXM1 in ALK-positive anaplastic large cell lymphoma: identification of a novel role for NPM1 in the pathobiology of NPM-ALK.

Haque, M., Li,J., Huang, Y-H., Almowaled, M., Barger, C.J., Karpf,A.R., Wang, P., Chen, W., Turner, S.D. and Lai,

1. Cancers (2019), In press

Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.

Torossian A, Broin N, Frentzel J, Daugrois C, Gandarillas S, Saati TA, Lamant L, Brousset P, Giuriato S, Espinos E.

Haematologica. 2019 Jul;104(7):1428-1439. doi: 10.3324/haematol.2017.181966

Analysis of ALK, MYCN and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements.

Javanmardi N, Fransson S, Djos A, Umapathy G, Östensson M, Milosevic J, Borenäs M, Hallberg B, Kogner P, Martinsson T, Palmer RH.

Genes Chromosomes Cancer. 2019 Jul 24. doi: 10.1002/gcc.22790.

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells.

Alam MW, Borenäs M, Lind DE, Cervantes-Madrid D, Umapathy G, Palmer RH, Hallberg B.

Front Oncol. 2019 Jul 5;9:579. doi: 10.3389/fonc.2019.00579.

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.

Gomez-Arteaga A, Margolskee E, Wei MT, van Besien K, Inghirami G, Horwitz S.

Leuk Lymphoma. 2019 Jul;60(7):1626-1631. doi: 10.1080/10428194.2019.1594220.

AP-1 Transcription Factors as Regulators of Immune Responses in Cancer.

Atsaves V, Leventaki V, Rassidakis GZ, Claret FX.

Cancers (Basel). 2019 Jul 23;11(7). pii: E1037. doi: 10.3390/cancers11071037.

From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK.

Larose H, Burke GAA, Lowe EJ, Turner SD.

Br J Haematol. 2019 Jun;185(6):1043-1054. doi: 10.1111/bjh.15763.

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma.

Singh VK, Werner S, Schwalm S, Lennerz V, Ruf S, Stadler S, Hackstein H, Reiter A, Wölfel T, Damm-Welk C, Woessmann W.

Oncoimmunologye1625688, 2019. https://doi.org/10.1080/2162402X.2019.1625688.

The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3.

Gambi G, Di Simone E, Basso V, Ricci L, Wang R, Verma A, Elemento O, Ponzoni M, Inghirami G, Icardi L, Mondino A.

Cancer Res. 2019 Jun 15;79(12):3076-3087. doi: 10.1158/0008-5472.CAN-18-0359.

PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.

Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Zhang M, Winter JN, Medeiros LJ, Rassidakis GZ, Vaupel CA, Li Y, Dakappagari N, Xu-Monette ZY, Young KH.

Mod Pathol. 2019 Jun;32(6):741-754. doi: 10.1038/s41379-018-0193-5.

Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.

Maura F, Agnelli L, Leongamornlert D, Bolli N, Chan WC, Dodero A, Carniti C, Heavican TB, Pellegrinelli A, Pruneri G, Butler A, Bhosle SG, Chiappella A, Di Rocco A, Zinzani PL, Zaja F, Piva R, Inghirami G, Wang W, Palomero T, Iqbal J, Neri A, Campbell PJ, Corradini P.

Am J Hematol. 2019 Jun;94(6):628-634. doi: 10.1002/ajh.25450.

Targeting anaplastic lymphoma kinase in neuroblastoma.

Umapathy G, Mendoza-Garcia P, Hallberg B, Palmer RH.

APMIS. 2019 May;127(5):288-302. doi: 10.1111/apm.12940.

Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.

Della Starza I, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, Menale L, Soscia R, Apicella V, Ilari C, Vitale A, Testi AM, Inghirami G, Chiaretti S, Foà R, Guarini A.

Leuk Lymphoma. 2019 May 3:1-3. doi: 10.1080/10428194.2019.1607325.

Opportunities and challenges of circulating biomarkers in neuroblastoma.

Trigg RM, Shaw JA, Turner SD.

Open Biol. 2019 May 31;9(5):190056. doi: 10.1098/rsob.190056.

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.
Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R.

Haematologica.

2019. doi: 10.3324/haematol.2019.216986.

Is breast implant-associated anaplastic large cell lymphoma a hazard of breast implant surgery?

Fitzal F, Turner SD, Kenner L.

Open Biol. 2019 Apr 26;9(4):190006. doi: 10.1098/rsob.190006.

Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.

Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodríguez-Perales S, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkær K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH.

Cancer Immunol Res. 2019 Apr;7(4):644-657. doi: 10.1158/2326-6066.CIR-18-0439.

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.

Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, Zhang W, Li Y, Dave BJ, Nairismägi ML, Greiner TC, Vose J, Weisenburger DD, Lachel C, Wang C, Fu K, Stevens JM, Lim ST, Ong CK, Gascoyne RD, Missiaglia E, Lemonnier F, Haioun C, Hartmann S, Pedersen MB, Laginestra MA, Wilcox RA, Teh BT, Yoshida N, Ohshima K, Seto M, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, d’Amore F, Inghirami G, Bertoni F, de Leval L, Gaulard P, Staudt LM, McKeithan TW, Pileri S, Chan WC, Iqbal J.F

Blood. 2019 Apr 11;133(15):1664-1676. doi: 10.1182/blood-2018-09-872549.

Author Correction: The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.

Okada T, Sinha S, Esposito I, Schiavon G, López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M, Okada M, Viale A, Heguy A, Socci ND, Sapino A, Seshan VE, Long S, Inghirami G, Rosen N, Giancotti FG.

Nat Cell Biol. 2019 Apr;21(4):534. doi: 10.1038/s41556-019-0288-3.

Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.

Laginestra MA, Cascione L, Motta G, Fuligni F, Agostinelli C, Rossi M, Sapienza MR, Righi S, Broccoli A, Indio V, Melle F, Tabanelli V, Calleri A, Novero D, Facchetti F, Inghirami G, Sabattini E, Bertoni F, Pileri SA.

Mod Pathol. 2019 Apr 25. doi: 10.1038/s41379-019-0279-8.

CD38 is not expressed in pediatric ALK-positive anaplastic large cell lymphoma.

Au-Yeung RKH, Burkhardt B, Woessmann W, Klapper W.

Pediatr Blood Cancer. 2019 Mar;66(3):e27541. doi: 10.1002/pbc.27541.

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.

Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling L, Dittus C, Chen Z, Huang X, Inghirami G, DiLiberto M, Chen-Kiang S, Leonard JP.

Blood. 2019 Mar 14;133(11):1201-1204. doi: 10.1182/blood-2018-11-886457.

Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death.

Garcia-Bermudez J, Baudrier L, Bayraktar EC, Shen Y, La K, Guarecuco R, Yucel B, Fiore D, Tavora B, Freinkman E, Chan SH, Lewis C, Min W, Inghirami G, Sabatini DM, Birsoy K.

Nature. 2019 Mar;567(7746):118-122. doi: 10.1038/s41586-019-0945-5.

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O.

Leukemia. 2019 Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1.

13PPhosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.

Umapathy G, Van den Eynden J, Cervantes-Madrid D, Szydzik J, Guan J, Palmer RH, Hallberg B.

Ann Oncol. 2019 Feb 1;30(Supplement_1). pii: mdz029.006. doi: 10.1093/annonc/mdz029.006.

Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.

Menotti M, Ambrogio C, Cheong TC, Pighi C, Mota I, Cassel SH, Compagno M, Wang Q, Dall’Olio R, Minero VG, Poggio T, Sharma GG, Patrucco E, Mastini C, Choudhari R, Pich A, Zamo A, Piva R, Giliani S, Mologni L, Collings CK, Kadoch C, Gambacorti-Passerini C, Notarangelo LD, Anton IM, Voena C, Chiarle R.

Nat Med. 2019 Jan;25(1):130-140. doi: 10.1038/s41591-018-0262-9.

The Cellular Origins of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Implications for Immunogenesis.

Turner SD.

Aesthet Surg J. 2019 Jan 31;39(Supplement_1):S21-S27. doi: 10.1093/asj/sjy229.

Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis.

Hatzi K, Geng H, Doane AS, Meydan C, LaRiviere R, Cardenas M, Duy C, Shen H, Vidal MNC, Baslan T, Mohammad HP, Kruger RG, Shaknovich R, Haberman AM, Inghirami G, Lowe SW, Melnick AM.

Nat Immunol. 2019 Jan;20(1):86-96. doi: 10.1038/s41590-018-0273-1.

Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.

Redaelli S, Ceccon M, Zappa M, Sharma GG, Mastini C, Mauri M, Nigoghossian M, Massimino L, Cordani N, Farina F, Piazza R, Gambacorti-Passerini C, Mologni L.

Cancer Res. 2018 Dec 15;78(24):6866-6880. doi: 10.1158/0008-5472.CAN-18-1867.

Comment on “ALK is a therapeutic target for lethal sepsis”.

Blasco RB, Patrucco E, Mota I, Tai WT, Chiarle R.

Sci Transl Med. 2018 Dec 12;10(471). pii: eaar4321. doi: 10.1126/scitranslmed.aar4321.

Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells.

Russo V, Paciocco A, Affinito A, Roscigno G, Fiore D, Palma F, Galasso M, Volinia S, Fiorelli A, Esposito CL, Nuzzo S, Inghirami G, de Franciscis V, Condorelli G.

Mol Ther Nucleic Acids. 2018 Dec 7;13:334-346. doi: 10.1016/j.omtn.2018.09.016.

TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.

Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontán L, Rivas MA, Pawlikowska P, Armand M, Mouly E, Torres-Martin M, Doane AS, Calvo Fernandez MT, Durant M, Della-Valle V, Teater M, Cimmino L, Droin N, Tadros S, Motanagh S, Shih AH, Rubin MA, Tam W, Aifantis I, Levine RL, Elemento O, Inghirami G, Green MR, Figueroa ME, Bernard OA, Aoufouchi S, Li S, Shaknovich R, Melnick AM.

Cancer Discov. 2018 Dec;8(12):1632-1653. doi: 10.1158/2159-8290.CD-18-0657.

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.

Van den Eynden J, Umapathy G, Ashouri A, Cervantes-Madrid D, Szydzik J, Ruuth K, Koster J, Larsson E, Guan J, Palmer RH, Hallberg B.

Sci Signal. 2018 Nov 20;11(557). pii: eaar5680. doi: 10.1126/scisignal.aar5680.

PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.

Lu X, Fernando TM, Lossos C, Yusufova N, Liu F, Fontán L, Durant M, Geng H, Melnick J, Luo Y, Vega F, Moy V, Inghirami G, Nimer S, Melnick AM, Lossos IS.

Blood. 2018 Nov 8;132(19):2026-2039. doi: 10.1182/blood-2018-02-831438.

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.

Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS.

Blood Cancer J. 2018 Nov 8;8(11):108. doi: 10.1038/s41408-018-0145-9.

Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma.

Knörr F, Weber S, Singh VK, Pulford K, Reiter A, Woessmann W, Damm-Welk C.

Clin Immunol. 2018 Oct;195:77-81. doi: 10.1016/j.clim.2018.07.008.

Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.

Fontán L, Qiao Q, Hatcher JM, Casalena G, Us I, Teater M, Durant M, Du G, Xia M, Bilchuk N, Chennamadhavuni S, Palladino G, Inghirami G, Philippar U, Wu H, Scott DA, Gray NS, Melnick A.

J Clin Invest. 2018 Oct 1;128(10):4397-4412. doi: 10.1172/JCI99436.

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.

Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI, Schaller T, Ng SB, Chng WJ, Yan B, Ng CH, Ravandi F, Andreeff M, Kantarjian HM, Medeiros LJ, Xagoraris I, Khoury JD.

Blood Cancer J. 2018 Oct 19;8(11):98. doi: 10.1038/s41408-018-0134-z.

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.

Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, Durek P, Anagnostopoulos I, Hummel M, Jöhrens K, Niedobitek A, Griffin PR, Piva R, Sczakiel HL, Woessmann W, Damm-Welk C, Hinze C, Stoiber D, Gillissen B, Turner SD, Kaergel E, von Hoff L, Grau M, Lenz G, Dörken B, Scheidereit C, Kenner L, Janz M, Mathas S.

Leukemia. 2018 Sep;32(9):1994-2007. doi: 10.1038/s41375-018-0045-9.

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.

Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, Durek P, Anagnostopoulos I, Hummel M, Jöhrens K, Niedobitek A, Griffin PR, Piva R, Sczakiel HL, Woessmann W, Damm-Welk C, Hinze C, Stoiber D, Gillissen B, Turner SD, Kaergel E, von Hoff L, Grau M, Lenz G, Dörken B, Scheidereit C, Kenner L, Janz M, Mathas S.

Leukemia. 2018 Sep;32(9):1994-2007. doi: 10.1038/s41375-018-0045-9.

Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas.

Poggio T, Duyster J, Illert AL.

Cancers (Basel). 2018 Sep 18;10(9). pii: E339. doi: 10.3390/cancers10090339.

Course of anti-ALK antibody titres during chemotherapy in children with anaplastic large cell lymphoma.

Mussolin L, Pillon M, Zimmermann M, Carraro E, Basso G, Knoerr F, Woessmann W, Damm-Welk C.

Br J Haematol. 2018 Sep;182(5):733-735. doi: 10.1111/bjh.14864.

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.

Guan J, Fransson S, Siaw JT, Treis D, Van den Eynden J, Chand D, Umapathy G, Ruuth K, Svenberg P, Wessman S, Shamikh A, Jacobsson H, Gordon L, Stenman J, Svensson PJ, Hansson M, Larsson E, Martinsson T, Palmer RH, Kogner P, Hallberg B.

Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4). pii: a002550. doi: 10.1101/mcs.a002550.

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.

Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T.

Oncogene. 2018 Aug;37(34):4639-4661. doi: 10.1038/s41388-018-0303-3.

Epigenetic biomarkers in cancer.

Egger G.

ESMO Open. 2018 Aug 3;3(5):e000416. doi: 10.1136/esmoopen-2018-000416.

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL.

Cheng S, Inghirami G, Cheng S, Tam W.

J Hematol Oncol. 2018 Aug 22;11(1):105. doi: 10.1186/s13045-018-0652-y.

Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.

Cascione L, Rinaldi A, Chiappella A, Kwee I, Ciccone G, Altenbuchinger M, Kohler C, Vitolo U, Inghirami G, Bertoni F.

Br J Haematol. 2018 Aug;182(3):453-456. doi: 10.1111/bjh.14817.

Expression Analysis of miR-29b in Malignant and Benign Breast Tumors: A Promising Prognostic Biomarker for Invasive Ductal Carcinoma With a Possible Histotype-Related Expression Status.

Papachristopoulou G, Papadopoulos EI, Nonni A, Rassidakis GZ, Scorilas A.

Clin Breast Cancer. 2018 Aug;18(4):305-312.e3. doi: 10.1016/j.clbc.2017.11.007.

Patient derived organoids to model rare prostate cancer phenotypes.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H.

Nat Commun. 2018 Jun 19;9(1):2404. doi: 10.1038/s41467-018-04495-z.

Alterations in the expression of DNA damage response-related molecules in potentially preneoplastic oral epithelial lesions.

Nikitakis NG, Rassidakis GZ, Tasoulas J, Gkouveris I, Kamperos G, Daskalopoulos A, Sklavounou A.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jun;125(6):637-649. doi: 10.1016/j.oooo.2018.03.006.

Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.

Chiaretti S, Messina M, Grammatico S, Piciocchi A, Fedullo AL, Di Giacomo F, Peragine N, Gianfelici V, Lauretti A, Bareja R, Martelli MP, Vignetti M, Apicella V, Vitale A, Li LS, Salek C, Elemento O, Inghirami G, Weinstock DM, Guarini A, Foà R.

Br J Haematol. 2018 Jun;181(5):642-652. doi: 10.1111/bjh.15251.

Characterization and diagnostic application of genomic NPM-ALK fusion sequences in anaplastic large-cell lymphoma.

Krumbholz M, Woessmann W, Zierk J, Seniuk D, Ceppi P, Zimmermann M, Singh VK, Metzler M, Damm-Welk C.

Oncotarget. 2018 May 29;9(41):26543-26555. doi: 10.18632/oncotarget.25489.

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.

Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A Jr, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R.

Nat Commun. 2018 May 22;9(1):2024. doi: 10.1038/s41467-018-04356-9.

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.

Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM.

Am J Hematol. 2018 May;93(5):607-614. doi: 10.1002/ajh.25043.

Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma.

Tabbò F, Nottegar A, Guerrera F, Migliore E, Luchini C, Maletta F, Veronese N, Montagna L, Gaudiano M, Di Giacomo F, Filosso PL, Delsedime L, Ciccone G, Scarpa A, Sapino A, Oliaro A, Ruffini E, Inghirami G, Chilosi M.

Hum Pathol. 2018 May;75:167-178. doi: 10.1016/j.humpath.2018.01.017.

ALK in Neuroblastoma: Biological and Therapeutic Implications.

Trigg RM, Turner SD.

Cancers (Basel). 2018 Apr 10;10(4). pii: E113. doi: 10.3390/cancers10040113.

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma.

Stadler S, Singh VK, Knörr F, Damm-Welk C, Woessmann W.

Cancers (Basel). 2018 Apr 10;10(4). pii: E114. doi: 10.3390/cancers10040114.

The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL).

Montes-Mojarro IA, Steinhilber J, Bonzheim I, Quintanilla-Martinez L, Fend F.

Cancers (Basel). 2018 Apr 4;10(4). pii: E107. doi: 10.3390/cancers10040107.

Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.

Prokoph N, Larose H, Lim MS, Burke GAA, Turner SD.

Cancers (Basel). 2018 Mar 30;10(4). pii: E99. doi: 10.3390/cancers10040099.

Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm.

Xiao P, Dolinska M, Sandhow L, Kondo M, Johansson AS, Bouderlique T, Zhao Y, Li X, Dimitriou M, Rassidakis GZ, Hellström-Lindberg E, Minato N, Walfridsson J, Scadden DT, Sigvardsson M, Qian H.

Blood Adv. 2018 Mar 13;2(5):534-548. doi: 10.1182/bloodadvances.2017013599.

The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.

Garces de Los Fayos Alonso I, Liang HC, Turner SD, Lagger S, Merkel O, Kenner L.

Cancers (Basel). 2018 Mar 28;10(4). pii: E93. doi: 10.3390/cancers10040093.

Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Knörr F, Damm-Welk C, Ruf S, Singh VK, Zimmermann M, Reiter A, Woessmann W.

Haematologica. 2018 Mar;103(3):477-485. doi: 10.3324/haematol.2017.177972.

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability.

Lobello C, Bikos V, Janikova A, Pospisilova S.

Cancers (Basel). 2018 Mar 5;10(3). pii: E64. doi: 10.3390/cancers10030064.

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Sharma GG, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C, Chiarle R.

Cancers (Basel). 2018 Feb 28;10(3). pii: E62. doi: 10.3390/cancers10030062.

Are we ready to take full advantage of patient-derived tumor xenograft models?

Kyriakides PW, Inghirami G.

Hematol Oncol. 2018 Feb;36(1):24-27. doi: 10.1002/hon.2419. Epub 2017 May 23.

Pathogenesis of Peripheral T Cell Lymphoma.

Pizzi M, Margolskee E, Inghirami G.

Annu Rev Pathol. 2018 Jan 24;13:293-320. doi: 10.1146/annurev-pathol-020117-043821.

AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis.

Teater M, Dominguez PM, Redmond D, Chen Z, Ennishi D, Scott DW, Cimmino L, Ghione P, Chaudhuri J, Gascoyne RD, Aifantis I, Inghirami G, Elemento O, Melnick A, Shaknovich R.

Nat Commun. 2018 Jan 15;9(1):222. doi: 10.1038/s41467-017-02595-w.

IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.

Bandini C, Pupuleku A, Spaccarotella E, Pellegrino E, Wang R, Vitale N, Duval C, Cantarella D, Rinaldi A, Provero P, Di Cunto F, Medico E, Bertoni F, Inghirami G, Piva R.

Cancers (Basel). 2018 Jan 18;10(1). pii: E21. doi: 10.3390/cancers10010021.

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.

Circosta P, Elia AR, Landra I, Machiorlatti R, Todaro M, Aliberti S, Brusa D, Deaglio S, Chiaretti S, Bruna R, Gottardi D, Massaia M, Giacomo FD, Guarini AR, Foà R, Kyriakides PW, Bareja R, Elemento O, Chichili GR, Monteleone E, Moore PA, Johnson S, Bonvini E, Cignetti A, Inghirami G.

Oncoimmunology. 2018 Feb 8;7(4):e1341032. doi: 10.1080/2162402X.2017.1341032.

Blood cytokine concentrations of pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma patients.

Knörr F, Damm-Welk C, Ruf S, Singh VK, Zimmermann M, Reiter A, Woessmann W.

Haematologica. 2017 Dec 14. pii: haematol.2017.177972.

MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.

Umapathy G, Guan J, Gustafsson DE, Javanmardi N, Cervantes-Madrid D, Djos A, Martinsson T, Palmer RH, Hallberg B.

Sci Signal. 2017 Nov 28;10(507). pii: eaam7550. doi: 10.1126/scisignal.aam7550.

Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma.

Rigaud C, Abbou S, Minard-Colin V, Geoerger B, Scoazec JY, Vassal G, Jaff N, Heuberger L, Valteau-Couanet D, Brugieres L.

Pediatr Blood Cancer. 2017 Nov 28.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ.

Cancer Res. 2017 Nov 1;77(21):e62-e66. doi: 10.1158/0008-5472.CAN-17-0582.

Targeting Autophagy in ALK-Associated Cancers.

Frentzel J, Sorrentino D, Giuriato S.

Cancers (Basel). 2017 Nov 27;9(12). pii: E161. doi: 10.3390/cancers9120161.

An anaplastic cardiac large cell lymphoma: A case report and analysis of cardiac involvement in newly diagnosed non-Hodgkin’s lymphoma from the Czech Lymphoma Study Group (CLSG) database.

Lobello C., Janikova A., Kren L., Hermanová M., Sprlakova-Puková A., Krejci J., Pospisilova S., Pospisilova S., Hamouzova M., Belada D., Prochazka V., Duras J., Mocikova H. and Trneny M.

J Cancer Res Ther.

2017, 5(10):66-71. DOI: dx.doi.org/10.14312/2052-4994.2017-13

Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation.

Guan J, Yamazaki Y, Chand D, van Dijk JR, Ruuth K, Palmer RH, Hallberg B.

Cancers (Basel). 2017 Oct 30;9(11). pii: E149. doi: 10.3390/cancers9110149.

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer.

Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, Jänne PA, Chiarle R.

Oncotarget. 2017 Sep 23;8(54):92265-92274.

EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.

Schmidt J, Bonzheim I, Steinhilber J, Montes-Mojarro IA, Ortiz-Hidalgo C, Klapper W, Fend F, Quintanilla-Martínez L.

Lab Invest. 2017 Sep;97(9):1095-1102. doi: 10.1038/labinvest.2017.54.

Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data.

Gong Q, Wang C, Zhang W, Iqbal J, Hu Y, Greiner TC, Cornish A, Kim JH, Rabadan R, Abate F, Wang X, Inghirami GG, McKeithan TW, Chan WC.

Sci Rep. 2017 Sep 12;7(1):11301. doi: 10.1038/s41598-017-11310-0.

Course of anti-ALK antibody titres during chemotherapy in children with anaplastic large cell lymphoma.

Mussolin L, Pillon M, Zimmermann M, Carraro E, Basso G, Knoerr F, Woessmann W, Damm-Welk C.

Br J Haematol. 2017 Aug 31.

Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.

Hoareau-Aveilla C, Meggetto F.

Cancers (Basel). 2017 Aug 3;9(8).

When the guardian sleeps: Reactivation of the p53 pathway in cancer.

Merkel O, Taylor N, Prutsch N, Staber PB, Moriggl R, Turner SD, Kenner L.

Mutat Res. 2017 Jul;773:1-13.

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.

Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ.

Leukemia. 2017 Jul;31(7):1633-1637. doi: 10.1038/leu.2017.103.

Patient-derived tumor xenografts of lymphoproliferative disorders: are they surrogates for the human disease?

Pizzi M, Inghirami G.

Curr Opin Hematol. 2017 Jul;24(4):384-392. doi: 10.1097/MOH.0000000000000349.

Anaplastic large-cell lymphoma and peripheral T-cell lymphoma: What can pediatricians and adult oncologists learn from each other?

Brugieres L, Bruneau J.

Hematol Oncol. 2017 Jun;35 Suppl 1:70-75.

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.

Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S.

Nat Commun. 2017 Jun 9;8:15618. doi: 10.1038/ncomms15618.

OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes.

Piazza R, Ramazzotti D, Spinelli R, Pirola A, De Sano L, Ferrari P, Magistroni V, Cordani N, Sharma N, Gambacorti-Passerini C.

Sci Rep. 2017 Apr 7;7:46290. doi: 10.1038/srep46290. Erratum in: Sci Rep. 2017 May 22;7:46823.

Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis.

Nottegar A, Tabbò F, Luchini C, Guerrera F, Gaudiano M, Bria E, Brunelli M, Chilosi M, Inghirami G.

Exp Mol Pathol. 2017 Apr;102(2):276-279. doi: 10.1016/j.yexmp.2017.02.014.

Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.

Wurster KD, Hummel F, Richter J, Giefing M, Hartmann S, Hansmann ML, Kreher S, Köchert K, Krappmann D, Klapper W, Hummel M, Wenzel SS, Lenz G, Janz M, Dörken B, Siebert R, Mathas S.

Leukemia. 2017 Mar;31(3):602-613.

The heterogeneous landscape of ALK negative ALCL.

Mereu E, Pellegrino E, Scarfò I, Inghirami G, Piva R.

Oncotarget. 2017 Mar 14;8(11):18525-18536. doi: 10.18632/oncotarget.14503.

NPM-ALK expression levels identify two distinct subtypes of paediatric anaplastic large cell lymphoma.

Pomari E, Basso G, Bresolin S, Pillon M, Carraro E, d’Amore ES, Viola G, Frasson C, Basso K, Bonvini P, Mussolin L.

Leukemia. 2017 Feb;31(2):498-501.

Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.

Guan J, Wolfstetter G, Siaw J, Chand D, Hugosson F, Palmer RH, Hallberg B.

Oncotarget. 2017 Feb 14;8(7):11566-11578. doi: 10.18632/oncotarget.14141.

Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-Vidal MN, Phillip J, Pera B, Yang SN, Takpradit K, Roman L, Gaudiano M, Crescenzo R, Ruan J, Inghirami G, Zhang T, Cremaschi G, Gray NS, Cerchietti L.

Nat Commun. 2017 Feb 20;8:14747. doi: 10.1038/ncomms14747.

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-Vidal MN, Phillip J, Pera B, Yang SN, Takpradit K, Roman L, Gaudiano M, Crescenzo R, Ruan J, Inghirami G, Zhang T, Cremaschi G, Gray NS, Cerchietti L.

Nat Commun. 2017 Jan 30;8:14290. doi: 10.1038/ncomms14290.

Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells.

Cao Z, Scandura JM, Inghirami GG, Shido K, Ding BS, Rafii S.

Cancer Cell. 2017 Jan 9;31(1):110-126. doi: 10.1016/j.ccell.2016.11.010.

Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.

Abate F, da Silva-Almeida AC, Zairis S, Robles-Valero J, Couronne L, Khiabanian H, Quinn SA, Kim MY, Laginestra MA, Kim C, Fiore D, Bhagat G, Piris MA, Campo E, Lossos IS, Bernard OA, Inghirami G, Pileri S, Bustelo XR, Rabadan R, Ferrando AA, Palomero T.

Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):764-769. doi: 10.1073/pnas.1608839114.

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.

Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, Odore E, Rezai K, Bekradda M, Inghirami G, D’Incalci M, Noel K, Cvitkovic E, Raymond E, Bertoni F.

Oncotarget. 2016 Dec 20;7(51):84675-84687. doi: 10.18632/oncotarget.13181.

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.

Redaelli S, Ceccon M, Antolini L, Rigolio R, Pirola A, Peronaci M, Gambacorti-Passerini C, Mologni L.

Oncotarget. 2016 Nov 8;7(45):72886-72897.

Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment.

Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen SS, Arruga F, Brusa D, Coscia M, Jaksic O, Inghirami G, Rossi D, Furman RR, Robson SC, Gaidano G, Chiorazzi N, Deaglio S.

Blood Adv. 2016 Nov 22;1(1):47-61. doi: 10.1182/bloodadvances.2016000984.

JAK-STAT signaling in cancer: From cytokines to non-coding genome.

Pencik J, Pham HT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F, Kenner L.

Cytokine. 2016 Nov;87:26-36.

Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.

K Singh V, Werner S, Hackstein H, Lennerz V, Reiter A, Wölfel T, Damm-Welk C, Woessmann W.

Clin Exp Immunol. 2016 Oct;186(1):96-105.

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Boi M, Todaro M, Vurchio V, Yang SN, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M, Cerchietti L, Elemento O, Riveiro ME, Cvitkovic E, Bertoni F, Inghirami G; AIRC 5xMille Consortium ‘Genetics-Driven Targeted Management of Lymphoid Malignancies’..

Oncotarget. 2016 Oct 25.

Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report.

Hebart H, Lang P, Woessmann W.

Ann Intern Med. 2016 Oct 18;165(8):607-608.

Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.

Wurster KD, Hummel F, Richter J, Giefing M, Hartmann S, Hansmann ML, Kreher S, Köchert K, Krappmann D, Klapper W, Hummel M, Wenzel SS, Lenz G, Janz M, Dörken B, Siebert R, Mathas S.

Leukemia. 2016 Oct 14.

Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling.

Hassler MR, Pulverer W, Lakshminarasimhan R, Redl E, Hacker J, Garland GD, Merkel O, Schiefer AI, Simonitsch-Klupp I, Kenner L, Weisenberger DJ, Weinhaeusel A, Turner SD, Egger G.

Cell Rep. 2016 Oct 4;17(2):596-608.

The role of the ALK receptor in cancer biology.

Hallberg B, Palmer RH.

Ann Oncol. 2016 Sep;27 Suppl 3:iii4-iii15.

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.

Redaelli S, Ceccon M, Antolini L, Rigolio R, Pirola A, Peronaci M, Gambacorti-PasseriniC, Mologni L.

Oncotarget. 2016 Sep 20.

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.

Guan J, Tucker ER, Wan H, Chand D, Danielson LS, Ruuth K, El Wakil A, Witek B, Jamin Y, Umapathy G, Robinson SP, Johnson TW, Smeal T, Martinsson T, Chesler L, Palmer RH, Hallberg B.

Dis Model Mech. 2016 Sep 1;9(9):941-52.

Lymphoma in Adolescents and Young Adults.

Brugières L, Brice P.

Prog Tumor Res. 2016;43:101-14.

Non-Hodgkin’s lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents.

Attarbaschi A, Carraro E, Abla O, Barzilai-Birenboim S, Bomken S, Brugieres L, Bubanska E, Burkhardt B, Chiang AK, Csoka M, Fedorova A, Jazbec J, Kabickova E, Krenova Z, Lazic J, Loeffen J, Mann G, Niggli F, Miakova N, Osumi T, Ronceray L, Uyttebroeck A, Williams D, Woessmann W, Wrobel G, Pillon M.

Haematologica. 2016 Aug 11.

Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.

Ceccon M, Merlo ME, Mologni L, Poggio T, Varesio LM, Menotti M, Bombelli S, Rigolio R, Manazza AD, Di Giacomo F, Ambrogio C, Giudici G, Casati C, Mastini C, Compagno M, Turner SD, Gambacorti-Passerini C, Chiarle R, Voena C.

Oncogene. 2016 Jul 21;35(29):3854-65.

Analysis of NPM-ALK-reactive CD8-positive T cell responses in children with NPM-ALK positive anaplastic large cell lymphoma.

Singh VK, Werner S, Hackstein H, Lennerz V, Reiter A, Wölfel T, Damm-Welk C, Woessmann W.

Clin Exp Immunol. 2016 Jul 14.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183.

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK.

Damm-Welk C, Siddiqi F, Fischer M, Hero B, Narayanan V, Camidge DR, Harris M,

Burke A, Lehrnbecher T, Pulford K, Oschlies I, Siebert R, Turner S, Woessmann J

Cancer. 2016 Jun 30;7(11):1383-7.

Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1.

Voena C, Varesio LM, Zhang L, Menotti M, Poggio T, Panizza E, Wang Q, Minero VG, Fagoonee S, Compagno M, Altruda F, Monti S, Chiarle R.

Oncotarget. 2016 May 31;7(22):33316-30.

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.

Siaw JT, Wan H, Pfeifer K, Rivera VM, Guan J, Palmer RH, Hallberg B.

Oncotarget. 2016 May 17;7(20):29011-22.

Anaplastic large cell lymphoma in paediatric and young adult patients.

Turner SD, Lamant L, Kenner L, Brugières L.

Br J Haematol. 2016 May;173(4):560-72.

Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice.

Choudhari R, Minero VG, Menotti M, Pulito R, Brakebusch C, Compagno M, Voena C, Ambrogio C, Chiarle R.

Blood. 2016 Mar 10;127(10):1297-306.

Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.

Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, Traverse-Glehen A, Rousset T, Quintin-Roue I, Petrella T, Emile JF, Amara N, Rochaix P, Chenard-Neu MP, Tasei AM, Menet E, Chomarat H, Costes V, Andrac-Meyer L, Michiels JF, Chassagne-Clement C, de Leval L, Brousset P, Delsol G, Lamant L.

Ann Oncol. 2016 Feb;27(2):306-14.

Advances in cancer immunology and cancer immunotherapy.

Voena C, Chiarle R.

Discov Med. 2016 Feb;21(114):125-33.

Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts.

Scarfò I, Pellegrino E, Mereu E, Kwee I, Agnelli L, Bergaggio E, Garaffo G, Vitale N, Caputo M, Machiorlatti R, Circosta P, Abate F, Barreca A, Novero D, Mathew S, Rinaldi A, Tiacci E, Serra S, Deaglio S, Neri A, Falini B, Rabadan R, Bertoni F, Inghirami G, Piva R; European TCell Lymphoma Study Group.

Blood. 2016 Jan 14;127(2):221-32.

Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress.

Malcolm TI, Villarese P, Fairbairn CJ, Lamant L, Trinquand A, Hook CE, Burke GA, Brugières L, Hughes K, Payet D, Merkel O, Schiefer AI, Ashankyty I, Mian S, Wasik M, Turner M, Kenner L, Asnafi V, Macintyre E, Turner SD.

Nat Commun. 2016 Jan 12;7:10087.

Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.

Gambacorti-Passerini C, Mussolin L, Brugieres L.

N Engl J Med. 2016 Jan 7;374(1):95-6.

ALK inhibitors for clinical use in cancer therapy.

Farina F, Gambacorti-Passerini C.

Front Biosci (Elite Ed). 2016 Jan 1;8:46-60.

The emerging role of CD30 and p53 as novel targets for therapy in anaplastic large cell lymphoma.

Rassidakis GZ, Drakos E.

Front Biosci (Elite Ed). 2016 Jan 1;8:61-71.

Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.

Voena C, Menotti M, Mastini C, Di Giacomo F, Longo DL, Castella B, Merlo ME, Ambrogio C, Wang Q, Minero VG, Poggio T, Martinengo C, D’Amico L, Panizza E, Mologni L, Cavallo F, Altruda F, Butaney M, Capelletti M, Inghirami G, Jänne PA, Chiarle R.

Cancer Immunol Res. 2015 Dec;3(12):1333-43.

Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.

Atsaves V, Zhang R, Ruder D, Pan Y, Leventaki V, Rassidakis GZ, Claret FX.

Leukemia. 2015 Nov;29(11):2162-72.

FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase.

Guan J, Umapathy G, Yamazaki Y, Wolfstetter G, Mendoza P, Pfeifer K, Mohammed A, Hugosson F, Zhang H, Hsu AW, Halenbeck R, Hallberg B, Palmer RH.

Elife. 2015 Sep 29;4:e09811.

Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead.

Minard-Colin V, Brugières L, Reiter A, Cairo MS, Gross TG, Woessmann W, Burkhardt B, Sandlund JT, Williams D, Pillon M, Horibe K, Auperin A, Le Deley MC, Zimmerman M, Perkins SL, Raphael M, Lamant L, Klapper W, Mussolin L, Poirel HA, Macintyre E, Damm-Welk C, Rosolen A, Patte C.

J Clin Oncol. 2015 Sep 20;33(27):2963-74.

Stem cell hunt in NHL.

Merkel O, Kenner L, Turner SD.

Oncoscience. 2015 Sep 3;2(10):809-10.

Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Hoareau-Aveilla C, Valentin T, Daugrois C, Quelen C, Mitou G, Quentin S, Jia J, Spicuglia S, Ferrier P, Ceccon M, Giuriato S, Gambacorti-Passerini C, Brousset P, Lamant L, Meggetto F.

J Clin Invest. 2015 Sep 1;125(9):3505-18.

Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.

Mitou G, Frentzel J, Desquesnes A, Le Gonidec S, AlSaati T, Beau I, Lamant L, Meggetto F, Espinos E, Codogno P, Brousset P, Giuriato S.

Oncotarget. 2015 Aug 17.

The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant Neurolaena lobata (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF-κB-driven tumour intravasation.

Unger C, Kiss I, Vasas A, Lajter I, Kramer N, Atanasov AG, Nguyen CH, Chatuphonprasert W, Brenner S, Krieger S, McKinnon R, Peschel A, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, Diaz R, Frisch R, Dirsch VM, Jäger W, de Martin R, Bochkov VN, Passreiter CM, Peter-Vörösmarty B, Mader RM, Grusch M, Dolznig H, Kopp B, Zupko I, Hohmann J, Krupitza G.

Phytomedicine. 2015 Aug 15;22(9):862-74.

Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.

Merkel O, Hamacher F, Griessl R, Grabner L, Schiefer AI, Prutsch N, Baer C, Egger G, Schlederer M, Krenn PW, Hartmann TN, Simonitsch-Klupp I, Plass C, Staber PB, Moriggl R, Turner SD, Greil R, Kenner L.

J Pathol. 2015 Aug;236(4):445-56.

The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant Neurolaena lobata (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF-κB-driven tumour intravasation.

Unger C, Kiss I, Vasas A, Lajter I, Kramer N, Atanasov AG, Nguyen CH, Chatuphonprasert W, Brenner S, Krieger S, McKinnon R, Peschel A, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, Diaz R, Frisch R, Dirsch VM, Jäger W, de Martin R, Bochkov VN, Passreiter CM, Peter-Vörösmarty B, Mader RM, Grusch M, Dolznig H, Kopp B, Zupko I, Hohmann J, Krupitza G.

Phytomedicine. 2015 Aug 15;22(9):862-74.

Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.

Merkel O, Hamacher F, Griessl R, Grabner L, Schiefer AI, Prutsch N, Baer C, Egger G, Schlederer M, Krenn PW, Hartmann TN, Simonitsch-Klupp I, Plass C, Staber PB, Moriggl R, Turner SD, Greil R, Kenner L.

J Pathol. 2015 Aug;236(4):445-56.

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

Fontana D, Ceccon M, Gambacorti-Passerini C, Mologni L.

Cancer Med. 2015 Jul;4(7):953-65.

Twenty years of modelling NPM-ALK-induced lymphomagenesis.

Giuriato S, Turner SD.

Front Biosci (Schol Ed). 2015 Jun 1;7:236-47.

The role of AP-1 and epigenetics in ALCL.

Schiefer AI, Vesely P, Hassler MR, Egger G, Kenner L.

Front Biosci (Schol Ed). 2015 Jun 1;7:226-35.

Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK.

Damm-Welk C, Pillon M, Woessmann W, Mussolin L.

Front Biosci (Schol Ed). 2015 Jun 1;7:205-16.

ALK-mediated post-transcriptional regulation: focus on RNA-binding proteins.

Bergalet J, Fawal M, Morello D, Espinos E.

Front Biosci (Landmark Ed). 2015 Jun 1;20:1250-8.

The anaplastic lymphoma kinase as an oncogene in solid tumors.

Voena C, Peola S, Chiarle R.

Front Biosci (Schol Ed). 2015 Jun 1;7:269-82.

The origins of ALK translocations.

Roukos V, Mathas S.

Front Biosci (Schol Ed). 2015 Jun 1;7:260-8.

MicroRNA and ALK-positive anaplastic large cell lymphoma.

Hoareau-Aveilla C, Merkel O, Meggetto F.

Front Biosci (Schol Ed). 2015 Jun 1;7:217-25.

ALK-positive anaplastic large cell lymphoma: an evolving story.

Bonzheim I, Steinhilber J, Fend F, Lamant L, Quintanilla-Martinez L.

Front Biosci (Schol Ed). 2015 Jun 1;7:248-59.

Twenty years of modelling NPM-ALK-induced lymphomagenesis.

Giuriato S, Turner SD.

Front Biosci (Schol Ed). 2015 Jun 1;7:236-47.

The role of AP-1 and epigenetics in ALCL.

Schiefer AI, Vesely P, Hassler MR, Egger G, Kenner L.

Front Biosci (Schol Ed). 2015 Jun 1;7:226-35.

MicroRNA and ALK-positive anaplastic large cell lymphoma.

Hoareau-Aveilla C, Merkel O, Meggetto F.

Front Biosci (Schol Ed). 2015 Jun 1;7:217-25.

Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK.

Damm-Welk C, Pillon M, Woessmann W, Mussolin L.

Front Biosci (Schol Ed). 2015 Jun 1;7:205-16.

ALK-mediated post-transcriptional regulation: focus on RNA-binding proteins.

Bergalet J, Fawal M, Morello D, Espinos E.

Front Biosci (Landmark Ed). 2015 Jun 1;20:1250-8.

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.

Abate F, Todaro M, van der Krogt JA, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A, Novero D, Gaudiano M, Aliberti S, Di Giacomo F, Tousseyn T, Lasorsa E, Crescenzo R, Bessone L, Ficarra E, Acquaviva A, Rinaldi A, Ponzoni M, Longo DL, Aime S, Cheng M, Ruggeri B, Piccaluga PP, Pileri S, Tiacci E, Falini B, Pera-Gresely B, Cerchietti L, Iqbal J, Chan WC, Shultz LD, Kwee I, Piva R, Wlodarska I, Rabadan R, Bertoni F, Inghirami G; European T-cell Lymphoma Study Group.

Leukemia. 2015 Jun;29(6):1390-401.

Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC.

Strullu M, Thomas C, Le Deley MC, Chevance A, Kanold J, Bertrand Y, Jubert C, Dalle JH, Paillard C, Baruchel A, Lamant L, Michel G, Brugières L.

Bone Marrow Transplant. 2015 Jun;50(6):795-801.

Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism.

Witek B, El Wakil A, Nord C, Ahlgren U, Eriksson M, Vernersson-Lindahl E, Helland Å, Alexeyev OA, Hallberg B, Palmer RH.

PLoS One. 2015 May 8;10(5):e0123542.

ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.

Lovisa F, Cozza G, Cristiani A, Cuzzolin A, Albiero A, Mussolin L, Pillon M, Moro S, Basso G, Rosolen A, Bonvini P.

PLoS One. 2015 Apr 13;10(4):e0121378.

Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Crescenzo R, Abate F, Lasorsa E, Tabbo’ F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo’ A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni F, Rabadan R, Inghirami G; European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium “Genetics-Driven Targeted Management of Lymphoid Malignancies”.

Cancer Cell. 2015 Apr 13;27(4):516-32.

Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin.

Moti N, Malcolm T, Hamoudi R, Mian S, Garland G, Hook CE, Burke GA, Wasik MA, Merkel O, Kenner L, Laurenti E, Dick JE, Turner SD.

Oncogene. 2015 Apr 2;34(14):1843-52.

Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.

Ceccon M, Mologni L, Giudici G, Piazza R, Pirola A, Fontana D, Gambacorti-Passerini C.

Mol Cancer Res. 2015 Apr;13(4):775-83.

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.

Mologni L, Ceccon M, Pirola A, Chiriano G, Piazza R, Scapozza L, Gambacorti-Passerini C.

Oncotarget. 2015 Mar 20;6(8):5720-34.

Next-generation sequencing identifies deregulation of microRNAs involved in both innate and adaptive immune response in ALK+ ALCL.

Steinhilber J, Bonin M, Walter M, Fend F, Bonzheim I, Quintanilla-Martinez L.

PLoS One. 2015 Feb 17;10(2):e0117780.

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, Javanmardi N, Abrahamsson J, Palmer RH, Noguera R, Hallberg B, Kogner P, Martinsson T.

Genes Chromosomes Cancer. 2015 Feb;54(2):99-109.

Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation.

Kiss I, Unger C, Huu CN, Atanasov AG, Kramer N, Chatruphonprasert W, Brenner S, McKinnon R, Peschel A, Vasas A, Lajter I, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, Diaz R, Frisch R, Dirsch VM, Jäger W, de Martin R, Bochkov VN, Passreiter CM, Peter-Vörösmarty B, Mader RM, Grusch M, Dolznig H, Kopp B, Zupko I, Hohmann J, Krupitza G.

Cancer Lett. 2015 Jan 28;356(2 Pt B):994-1006.

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.

Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dörken B, Dirnhofer S, Mathas S, Janz M, Emre NC, Rosenwald A, Ott G, Lenz P, Tzankov A, Lenz G.

Blood. 2015 Jan 1;125(1):124-32.

Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology.

Blasco RB, Karaca E, Ambrogio C, Cheong TC, Karayol E, Minero VG, Voena C, Chiarle R.

Cell Rep. 2014 Nov 20;9(4):1219-27.[/

The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.

Atsaves V, Lekakis L, Drakos E, Leventaki V, Ghaderi M, Baltatzis GE, Chioureas D, Jones D, Feretzaki M, Liakou C, Panayiotidis P, Gorgoulis V, Patsouris E, Medeiros LJ, Claret FX, Rassidakis GZ.

Br J Haematol. 2014 Nov;167(4):514-23. doi: 10.1111/bjh.13079.

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.

Umapathy G, El Wakil A, Witek B, Chesler L, Danielson L, Deng X, Gray NS, Johansson M, Kvarnbrink S, Ruuth K, Schönherr C, Palmer RH, Hallberg B.

Sci Signal. 2014 Oct 28;7(349):ra102.

Anaplastic large cell lymphoma (ALCL) and breast implants: breaking down the evidence.

Ye X, Shokrollahi K, Rozen WM, Conyers R, Wright P, Kenner L, Turner SD, Whitaker IS.

Mutat Res Rev Mutat Res. 2014 Oct-Dec;762:123-32. doi: 10.1016/j.mrrev.2014.08.002.

Monoallelic mutations of the perforin gene may represent a predisposing factor to childhood anaplastic large cell lymphoma.

Ciambotti B, Mussolin L, d’Amore ES, Pillon M, Sieni E, Coniglio ML, Ros MD, Cetica V, Aricò M, Rosolen A.

J Pediatr Hematol Oncol. 2014 Aug;36(6):e359-65.

Paediatric anaplastic large cell lymphoma with leukaemic presentation in children: a report of nine French cases.

Spiegel A, Paillard C, Ducassou S, Perel Y, Plantaz D, Strullu M, Eischen A, Lutz P, Lamant L, Le Deley MC, Brugières L.

Br J Haematol. 2014 May;165(4):545-51. doi: 10.1111/bjh.12777.

Clinical analysis and prognostic significance of haemophagocytic lymphohistiocytosis-associated anaplastic large cell lymphoma in children.

Pasqualini C, Minard-Colin V, Saada V, Lamant L, Delsol G, Patte C, Le Deley MC, Valteau-Couanet D, Brugières L.

Br J Haematol. 2014 Jan 21.

Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma.

Damm-Welk C, Mussolin L, Zimmermann M, Pillon M, Klapper W, Oschlies I, d’Amore ES, Reiter A, Woessmann W, Rosolen A.

Blood. 2014 Jan 16;123(3):334-7.

STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.

Spaccarotella E, Pellegrino E, Ferracin M, Ferreri C, Cuccuru G, Liu C, Iqbal J, Cantarella D, Taulli R, Provero P, Di Cunto F, Medico E, Negrini M, Chan WC, Inghirami G, Piva R.

Haematologica. 2014 Jan;99(1):116-24.

Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.

Marzec M, Halasa K, Liu X, Wang HY, Cheng M, Baldwin D, Tobias JW, Schuster SJ, Woetmann A, Zhang Q, Turner SD, Ødum N, Wasik MA.

J Immunol. 2013 Dec 15;191(12):6200-7.

Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.

Sattu K, Hochgräfe F, Wu J, Umapathy G, Schönherr C, Ruuth K, Chand D, Witek B, Fuchs J, Li PK, Hugosson F, Daly RJ, Palmer RH, Hallberg B.

FEBS J. 2013 Nov;280(21):5269-82.

PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma.

Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbò F, Piva R, Rancoita PM, Matolcsy A, Timar B, Tousseyn T, Rodríguez-Pinilla SM, Piris MA, Beà S, Campo E, Bhagat G, Swerdlow SH, Rosenwald A, Ponzoni M, Young KH, Piccaluga PP, Dummer R, Pileri S, Zucca E, Inghirami G, Bertoni F.

Blood. 2013 Oct 10;122(15):2683-93.

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Hallberg B, Palmer RH.

Nat Rev Cancer. 2013 Oct;13(10):685-700. doi: 10.1038/nrc3580. Review. Erratum in: Nat Rev Cancer. 2013 Nov;13(11):820.

Jeb/Alk signalling regulates the Lame duck GLI family transcription factor in the Drosophila visceral mesoderm.

Popichenko D, Hugosson F, Sjögren C, Dogru M, Yamazaki Y, Wolfstetter G, Schönherr C, Fallah M, Hallberg B, Nguyen H, Palmer RH.

Development. 2013 Aug;140(15):3156-66.

Jeb/Alk signalling regulates the Lame duck GLI family transcription factor in the Drosophila visceral mesoderm.

Popichenko D, Hugosson F, Sjögren C, Dogru M, Yamazaki Y, Wolfstetter G, Schönherr C, Fallah M, Hallberg B, Nguyen H, Palmer RH.

Development. 2013 Aug;140(15):3156-66.

Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.

Piazza R, Magistroni V, Mogavero A, Andreoni F, Ambrogio C, Chiarle R, Mologni L, Bachmann PS, Lock RB, Collini P, Pelosi G, Gambacorti-Passerini C.

Neoplasia. 2013 May;15(5):511-22.

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.

Chand D, Yamazaki Y, Ruuth K, Schönherr C, Martinsson T, Kogner P, Attiyeh EF, Maris J, Morozova O, Marra MA, Ohira M, Nakagawara A, Sandström PE, Palmer RH, Hallberg B.

Dis Model Mech. 2013 Mar;6(2):373-82.

Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.

Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C.

Mol Cancer Res. 2013 Feb;11(2):122-32.

Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis.

Mussolin L, Damm-Welk C, Pillon M, Zimmermann M, Franceschetto G, Pulford K, Reiter A, Rosolen A, Woessmann W.

Leukemia. 2013 Feb;27(2):416-22.

The dichloromethane extract of the ethnomedicinal plant Neurolaena lobata inhibits NPM/ALK expression which is causal for anaplastic large cell lymphomagenesis.

Unger C, Popescu R, Giessrigl B, Laimer D, Heider S, Seelinger M, Diaz R, Wallnöfer B, Egger G, Hassler M, Knöfler M, Saleh L, Sahin E, Grusch M, Fritzer-Szekeres M, Dolznig H, Frisch R, Kenner L, Kopp B, Krupitza G.

Int J Oncol. 2013 Jan;42(1):338-48.

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.

Schönherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V, Djos A, Martinsson T, Christensen JG, Palmer RH, Hallberg B.

Oncogene. 2012 Dec 13;31(50):5193-200.

PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.

Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L.

Nat Med. 2012 Nov;18(11):1699-704.

Targeted inactivation of nuclear interaction partner of ALK disrupts meiotic prophase.

Illert AL, Kawaguchi H, Antinozzi C, Bassermann F, Quintanilla-Martinez L, von Klitzing C, Hiwatari M, Peschel C, de Rooij DG, Morris SW, Barchi M, Duyster J.

Development. 2012 Jul;139(14):2523-34

Anaplastic lymphoma kinase in human cancer.

Schonherr C, Hallberg B, Palmer R.

Crit Rev Oncog. 2012;17(2):123-43. Review.

Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment.

Mazot P, Cazes A, Dingli F, Degoutin J, Irinopoulou T, Boutterin MC, Lombard B, Loew D, Hallberg B, Palmer RH, Delattre O, Janoueix-Lerosey I, Vigny M.

PLoS One. 2012;7(3):e33581.

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

Schönherr C, Ruuth K, Yamazaki Y, Eriksson T, Christensen J, Palmer RH, Hallberg B.

Biochem J. 2011 Dec 15;440(3):405

Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.

Di Paolo D, Ambrogio C, Pastorino F, Brignole C, Martinengo C, Carosio R, Loi M, Pagnan G, Emionite L, Cilli M, Ribatti D, Allen TM, Chiarle R, Ponzoni M, Perri P.

Mol Ther. 2011 Dec;19(12):2201-12.

Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.

Dejean E, Renalier MH, Foisseau M, Agirre X, Joseph N, de Paiva GR, Al Saati T, Soulier J, Desjobert C, Lamant L, Prósper F, Felsher DW, Cavaillé J, Prats H, Delsol G, Giuriato S, Meggetto F.

Leukemia. 2011 Dec;25(12):1882-90.

The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway.

Martinelli P, Bonetti P, Sironi C, Pruneri G, Fumagalli C, Raviele PR, Volorio S, Pileri S, Chiarle R, McDuff FK, Tusi BK, Turner SD, Inghirami G, Pelicci PG, Colombo E.

Blood. 2011 Jun 16;117(24):6617-26.

ALK and NSCLC: Targeted therapy with ALK inhibitors.

Hallberg B, Palmer RH.

F1000 Med Rep. 2011;3:21.

Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS.

Zhang Q, Wang H, Kantekure K, Paterson JC, Liu X, Schaffer A, Paulos C, Milone MC, Odum N, Turner S, Marafioti T, Wasik MA.

Blood. 2011 Sep 15;118(11):3062-71.

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis.

Mduff FK, Hook CE, Tooze RM, Huntly BJ, Pandolfi PP, Turner SD.

Lab Invest. 2011 Sep;91(9):1298-303.

The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo.

Schönherr C, Ruuth K, Eriksson T, Yamazaki Y, Ottmann C, Combaret V, Vigny M, Kamaraj S, Palmer RH, Hallberg B.

Transl Oncol. 2011 Aug;4(4):258-65.

MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.

Desjobert C, Renalier MH, Bergalet J, Dejean E, Joseph N, Kruczynski A, Soulier J, Espinos E, Meggetto F, Cavaillé J, Delsol G, Lamant L.

Blood. 2011 Jun 16;117(24):6627-37.

Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination.

Colomba A, Giuriato S, Dejean E, Thornber K, Delsol G, Tronchère H, Meggetto F, Payrastre B, Gaits-Iacovoni F.

Blood Cancer J. 2011 Jun;1(6):e21.

The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway.

Martinelli P, Bonetti P, Sironi C, Pruneri G, Fumagalli C, Raviele PR, Volorio S, Pileri S, Chiarle R, McDuff FK, Tusi BK, Turner SD, Inghirami G, Pelicci PG, Colombo E.

Blood. 2011 Jun 16;117(24):6617-26.

The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.

Mazot P, Cazes A, Boutterin MC, Figueiredo A, Raynal V, Combaret V, Hallberg B, Palmer RH, Delattre O, Janoueix-Lerosey I, Vigny M.

Oncogene. 2011 Apr 28;30(17):2017-25.

HuR-mediated control of C/EBPbeta mRNA stability and translation in ALK-positive anaplastic large cell lymphomas.

Bergalet J, Fawal M, Lopez C, Desjobert C, Lamant L, Delsol G, Morello D, Espinos E.

Mol Cancer Res. 2011 Apr;9(4):485-96.

Aberrant anaplastic lymphoma kinase activity induces a p53 and Rb-dependent senescence-like arrest in the absence of detectable p53 stabilization.

McDuff FK, Turner SD.

PLoS One. 2011 Mar 14;6(3):e17854.

Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.

Martinsson T, Eriksson T, Abrahamsson J, Caren H, Hansson M, Kogner P, Kamaraj S, Schönherr C, Weinmar J, Ruuth K, Palmer RH, Hallberg B.

Cancer Res. 2011 Jan 1;71(1):98-105.

Crizotinib–latest champion in the cancer wars?

Hallberg B, Palmer RH.

N Engl J Med. 2010 Oct 28;363(18):1760-2. doi: 10.1056/NEJMe1010404. No abstract available.

nvolvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.

Riera L, Lasorsa E, Ambrogio C, Surrenti N, Voena C, Chiarle R.

J Biol Chem. 2010 Aug 20;285(34):26441-50.

Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.

Giuriato S, Foisseau M, Dejean E, Felsher DW, Al Saati T, Demur C, Ragab A, Kruczynski A, Schiff C, Delsol G, Meggetto F.

Blood. 2010 May 20;115(20):4061-70.

Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells.

Schönherr C, Yang HL, Vigny M, Palmer RH, Hallberg B.

Oncogene. 2010 May 13;29(19):2817-30.

C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.

Anastasov N, Bonzheim I, Rudelius M, Klier M, Dau T, Angermeier D, Duyster J, Pittaluga S, Fend F, Raffeld M, Quintanilla-Martinez L.

Haematologica. 2010 May;95(5):760-7.

Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms.

Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, Fornari A, Martinoglio B, Medico E, Zamò A, Facchetti F, Ponzoni M, Geissinger E, Rosenwald A, Müller-Hermelink HK, De Wolf-Peeters C, Piccaluga PP, Pileri S, Neri A, Inghirami G.

J Clin Oncol. 2010 Mar 20;28(9):1583-90.

NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.

Ambrogio C, Martinengo C, Voena C, Tondat F, Riera L, di Celle PF, Inghirami G, Chiarle R.

Cancer Res. 2009 Nov 15;69(22):8611-9.

The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.

Bonvini P, Zorzi E, Mussolin L, Monaco G, Pigazzi M, Basso G, Rosolen A.

Haematologica. 2009 Jul;94(7):944-55.

Anaplastic lymphoma kinase: signalling in development and disease.

Palmer RH, Vernersson E, Grabbe C, Hallberg B.

Biochem J. 2009 May 27;420(3):345-61.

NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner.

Cui YX, Kerby A, McDuff FK, Ye H, Turner SD.

Blood. 2009 May 21;113(21):5217-27.

Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma.

Mathas S, Kreher S, Meaburn KJ, Jöhrens K, Lamprecht B, Assaf C, Sterry W, Kadin ME, Daibata M, Joos S, Hummel M, Stein H, Janz M, Anagnostopoulos I, Schrock E, Misteli T, Dörken B.

Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5831-6.

Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma.

Cannella S, Santoro A, Bruno G, Pillon M, Mussolin L, Mangili G, Rosolen A, Aricò M.

Cancer. 2007 Jun 15;109(12):2566-71.

ALK-positive plasmablastic B-cell lymphoma with the clathrin-ALK gene rearrangement.

Isimbaldi G, Bandiera L, d’Amore ES, Conter V, Milani M, Mussolin L, Rosolen A.

Pediatr Blood Cancer. 2006 Mar;46(3):390-1.

Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma.

Mussolin L, Pillon M, d’Amore ES, Santoro N, Lombardi A, Fagioli F, Zanesco L, Rosolen A.

Leukemia. 2005 Sep;19(9):1643-7.